New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 26, 2013
17:17 EDTLPDXLipoScience Chief Medical Officer to resign September 17
LipoScience disclosed that on August 20, Robert Honigberg, VP, medical affairs and Chief Medical Officer of the company, informed the company that he is resigning as an employee and executive officer of the company for family-related reasons, effective as of September 17.
News For LPDX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 25, 2014
09:13 EDTLPDXOn The Fly: Pre-market Movers
HIGHER: LipoScience (LPDX), up 63% after agreeing to be acquired by LabCorp (LH) for $5.25 per share in cash... Magnum Hunter (MHR), up 12.5% after announcing that throughput volumes on Eureka Hunter's gas gathering pipeline system have increased to about 316,500 MMBtu per day... Jabil Circuit (JBL), up 4.7% following its report of better than expected fourth EPS and revenue... JD.com (JD), up 0.7% after the stock was initiated with an Outperform rating at Macquarie. LOWER: Yahoo (YHOO), down 0.6% after RBC Capital downgraded its rating on the stock to Sector Perform from Outperform, saying the risk/reward is less attractive following Alibaba's (BABA) initial public offering... HB Fuller (FUL), down 15% after reporting quarterly results and guidance that missed analyst estimates... Omnova Solutions (OMN), down 10.8% after its Q3 adjusted EPS missed expectations... Pacira Pharmaceuticals (PCRX), down 9.2% after receiving an FDA warning letter over certain promotional materials on Exparel.
07:02 EDTLPDXLabCorp acquires LipoScience
LabCorp (LH) and LipoScience (LPDX) announced that they entered into a definitive merger agreement under which LabCorp would acquire LipoScience for a purchase price of $5.25 per share in cash, or a transaction value of $85.3M which represents a total enterprise value of approximately $63M. The Board of Directors of LipoScience has unanimously approved the agreement and recommended approval of the transaction by LipoScience’s stockholders. The transaction is subject to customary closing conditions including the expiration or early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and approval by LipoScience’s stockholders. The transaction is expected to close in Q4.
07:00 EDTLPDXLabCorp acquires LipoScience for $5.25 per share in cash
06:58 EDTLPDXLabCorp agrees to acquire LipoScience for $5.25 per share
Subscribe for More Information
06:56 EDTLPDXLabCorp to acquire LipoScience for $5.25 per share in all cash transaction
06:56 EDTLPDXLabCorp agrees to acquire LipoScience for $5.25 per share
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use